Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly and Co. (LLY) on Thursday reported fourth-quarter earnings of $4.41 billion. The Indianapolis-based company said it had profit of $4.88 per share. Earnings, adjusted for one-time gains and ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...